Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

<i>STK11</i> as an Emerging Biomarker in Non-Small Cell Lung Cancer.

Current oncology (Toronto, Ont.)·2026
Same author

Assessing the physiological relevance of the bioactivation of tobacco-specific carcinogen NNK and its metabolite NNAL: quantitative analyses of hydrolysis products from their protein adducts under different carcinogen exposure conditions.

Carcinogenesis·2026
Same author

Outcomes of extended reduced-dose apixaban versus full-dose apixaban in cancer-associated venous thromboembolism.

British journal of haematology·2026
Same author

Barriers and facilitators for cross-language telerehabilitation services: experiences of occupational and physical therapists.

Disability and rehabilitation·2026
Same author

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study.

Cancers·2026
Same author

YAP/TEAD inhibitor VT3989 in solid tumors: a phase 1/2 trial.

Nature medicine·2025

Related Experiment Video

Updated: Jul 19, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.2K

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer.

Libang Yang1, Adam Gilbertsen1, Blake Jacobson2

  • 1Department of Medicine, University of Minnesota, 420 Delaware Street, SE, Minneapolis, MN 55455, USA.

International Journal of Molecular Sciences
|August 12, 2023
PubMed
Summary

New research identifies SFPQ as a potential biomarker for lung cancer diagnosis and prognosis. Elevated SFPQ levels and its specific isoform location in advanced cancers show promise for early detection and monitoring.

Keywords:
DNA methylationELISAIHCSFPQcytoplasmic isoformmetastasisnon-small cell lung cancer (NSCLC)

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.6K

Related Experiment Videos

Last Updated: Jul 19, 2025

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.2K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K
Establishment of a Clinic-based Biorepository
07:50

Establishment of a Clinic-based Biorepository

Published on: May 29, 2017

6.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Proteins are the most common cancer markers, but specific markers for lung cancer are lacking.
  • Metastatic non-small-cell lung cancer (NSCLC) is a leading cause of cancer death.
  • Several proteins, including SFPQ, are upregulated in NSCLC cells compared to controls.

Purpose of the Study:

  • To investigate the potential of SFPQ as a diagnostic and prognostic marker for lung cancer.
  • To develop methods for detecting SFPQ and its isoforms.

Main Methods:

  • Quantitative analysis of protein expression in NSCLC cells versus control and inflammatory cells.
  • Development and application of Enzyme-Linked Immunosorbent Assays (ELISAs) for SFPQ detection.
  • Immunocytometry and Immunohistochemistry (IHC) for isoform localization and validation.

Main Results:

  • SFPQ showed the most significant expression difference between NSCLC and control/inflammatory cells.
  • A specific cytoplasmic SFPQ isoform was predominantly found in advanced cancers.
  • ELISA results were consistent with immunocytometry and IHC findings.
  • Enhanced DNA methylation in the SFPQ gene may contribute to expression differences.

Conclusions:

  • Elevated SFPQ levels and its specific isoform localization show potential as diagnostic and prognostic markers for lung cancer.
  • SFPQ detection could aid in clinical diagnosis, prognosis, and anti-drug monitoring for NSCLC.